Chaperonin-Containing T-Complex Polypeptide 1 Complex as A Drug Target for Neurodegenerative Diseases

Target Name: Chaperonin-containing T-complex polypeptde 1 complex (CCT)

NCBI ID: P16342

Chaperonin-containing T-complex polypeptde 1 complex (CCT)

Chaperonin-Containing T-Complex Polypeptide 1 Complex as A Drug Target for Neurodegenerative Diseases

Chaperonin-Containing T-Complex Polypeptide 1 Complex (CCT) as a Drug Target or Biomarker: A Promising Approach for the Treatment of Neurodegenerative Diseases

Abstract:

Chaperonin-containing T-complex polypeptide 1 complex (CCT) is a protein that contains a unique combination of chaperone and T-complex subunits, which provides unique properties in terms of its structure, stability, and function. CCT has been identified as a potential drug target or biomarker for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This article aims to provide an overview of CCT, its potential drug-target properties, and its potential as a biomarker for these diseases.

Introduction:

Neurodegenerative diseases are a group of disorders that affect the nervous system and result in a progressive loss of cognitive and motor function. These diseases include Alzheimer's disease, Parkinson's disease, and Huntington's disease, which have a significant impact on the quality of life for patients.

Despite the development of numerous treatments for these diseases, the standard of care remains limited. The search for new treatments and biomarkers has become a promising direction in the fight against neurodegenerative diseases.

Chaperonin-containing T-complex polypeptide 1 complex (CCT) is a protein that has attracted significant interest due to its unique structure and function. CCT is a 25kDa protein that contains a T-complex composed of the protein encoded by the gene ENSG0026 and a chaperone composed of the protein encoded by the gene FKBP1.

Structure and Function:

The structure of CCT is unique, as it combines the functions of a chaperone and a T-complex subunit in a single protein. CCT has a molecular weight of 25kDa and a pre-folds structure of 10.5kDa. It consists of a 155 amino acid residue that contains a T-complex and a chaperone region.

The T-complex subunit is composed of the protein encoded by the gene ENSG0026 and has a calculated pI of 11.8. The ENSG0026 protein is a nucleotide-binding protein that contains a nucleotide-binding domain and a catalytic domain. The catalytic domain is responsible for the binding of nucleotides to the protein.

The chaperone region of CCT is composed of the protein encoded by the gene FKBP1 and has a calculated pI of 13.2. FKBP1 is a protein that contains a nucleotide-binding domain, a catalytic domain, and a carboxy-terminal domain. The nucleotide-binding domain is responsible for the binding of nucleotides to the protein, the catalytic domain is responsible for the catalytic activity of the protein, and the carboxy-terminal domain is responsible for the stability of the protein.

CCT has been shown to have various functions, including the regulation of protein stability, the regulation of protein-protein interactions, and the regulation of DNA replication.

Potential Drug Target:

CCT has been identified as a potential drug target for the treatment of neurodegenerative diseases. Its unique structure and function make it an attractive target for small molecules that can modulate its activity.

One of the potential mechanisms by which CCT can be targeted is by modulating its stability. CCT can be stabilized by various small molecules, including inhibitors of protein tyrosination, which can modulate its stability and activity.

Another potential mechanism by which CCT can be targeted is by modulating its function. CCT can be modified by small molecules that alter its nucleotide-binding domain, its catalytic domain, or its carboxy-terminal domain. These modifications can alter its

Protein Name: Chaperonin-containing T-complex Polypeptde 1 Complex (CCT)

The "Chaperonin-containing T-complex polypeptde 1 complex (CCT) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Chaperonin-containing T-complex polypeptde 1 complex (CCT) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets